Achievement of Minimal Symptom Expression and Effect on Disease-specific Measures in Acetylcholine Receptor Antibody-positive Participants with Generalized Myasthenia Gravis Treated with Efgartigimod in ADAPT/ADAPT+ (P10-11.009)

To assess incidence, characteristics, and changes in generalized myasthenia gravis (gMG)-specific scales in participants achieving minimal symptom expression (MSE) in the phase 3 study of intravenous efgartigimod, ADAPT, and its open-label extension, ADAPT+.